Project Grant R01HD111848
Award Date 9/13/23
Completion Date 8/31/26
Dollars Obligated $2M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
College Station, TX 77843, USA
Similar Awards
- The Project Grant award of $451,000.00 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) is funding research at the University of Texas Southwestern Medical Center (UT Southwestern) to identify genes on human chromosome 21 that contribute to the neurological and developmental impairments associated with Down syndrome. The 2-year project will use CRISPR interference (CRISPRi) technology and induced pluripotent stem cells (iPSCs) derived from individuals...
- This $1,633,451 federal Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) will fund a research project at Texas A&M AgriLife Research to determine the cell-specific mechanisms driving aberrant bone regeneration in Down syndrome. The 3-year project aims to characterize the transcriptome, osteoclast/osteoblast activity, and sexually dimorphic impacts on bone healing in multiple murine models of Down syndrome. The research will...
- This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
- This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $429,000 to the Regents of the University of Michigan to conduct research on the molecular regulators of the GABAergic system in human neurons derived from control and trisomy 21 (Down syndrome) human embryonic stem cells. The primary goal is to discover the underlying mechanisms that cause...
- The Trustees of the University of Pennsylvania received a $3.7 million Project Grant award from the Department of Health and Human Services National Institutes of Health Office of the Director to address co-occurring conditions in individuals with Down syndrome. Funded under the Trans-NIH Research Support program (CFDA 93.310), the three-year project will test whether reducing proteostatic stress with the FDA-approved small molecule 4-phenylbutyrate can ameliorate sleep deficits, metabolic...
- The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
- The Department of Health and Human Services National Institutes of Health (NIH) awarded a $1,488,578 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the University of Wisconsin-Madison to develop humanized mouse models for studying Down syndrome (DS) immune responses. The project aims to: 1) Create DS hypoimmune gene-edited induced pluripotent stem cell lines and differentiate them into cardiovascular cell therapies, assessing in vitro DS immune responses; and 2)...
- This Project Grant award, funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), is focused on investigating the susceptibility of basal forebrain cholinergic neurons in individuals with Down syndrome. The key objectives of this $111,783 award, which runs from November 9, 2024 to June 30, 2026, are to: 1) determine if there are fewer basal forebrain cholinergic neurons and earlier accumulation of Alzheimer's disease pathology in the early...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,257,163 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) as a potential treatment for Alzheimer's disease in individuals with Down syndrome. The 5-year project, beginning on Jul 1, 2025, will first measure FSH levels across the lifespan in mouse models of Down syndrome...
- This federal Project Grant award for $152,816.00, provided by the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research), aims to investigate the link between Down's syndrome (trisomy 21) and placentation defects. The research will focus on: Identifying transcriptional differences in implantation-stage trophoblasts between trisomy 21 and euploid induced pluripotent stem cell lines through RNA-sequencing. Assessing the...